Literature DB >> 33302377

Lactoferrin and Its Derived Peptides: An Alternative for Combating Virulence Mechanisms Developed by Pathogens.

Daniela Zarzosa-Moreno1, Christian Avalos-Gómez1,2, Luisa Sofía Ramírez-Texcalco3, Erick Torres-López3, Ricardo Ramírez-Mondragón3, Juan Omar Hernández-Ramírez3, Jesús Serrano-Luna1, Mireya de la Garza1.   

Abstract

Due to the emergence of multidrug-resistant pathogens, it is necessary to develop options to fight infections caused by these agents. Lactoferrin (Lf) is a cationic nonheme multifunctional glycoprotein of the innate immune system of mammals that provides numerous benefits. Lf is bacteriostatic and/or bactericidal, can stimulate cell proliferation and differentiation, facilitate iron absorption, improve neural development and cognition, promote bone growth, prevent cancer and exert anti-inflammatory and immunoregulatory effects. Lactoferrin is present in colostrum and milk and is also produced by the secondary granules of polymorphonuclear leukocytes, which store this glycoprotein and release it at sites of infection. Lf is also present in many fluids and exocrine secretions, on the surfaces of the digestive, respiratory and reproductive systems that are commonly exposed to pathogens. Apo-Lf (an iron-free molecule) can be microbiostatic due to its ability to capture ferric iron, blocking the availability of host iron to pathogens. However, apo-Lf is mostly microbicidal via its interaction with the microbial surface, causing membrane damage and altering its permeability function. Lf can inhibit viral entry by binding to cell receptors or viral particles. Lf is also able to counter different important mechanisms evolved by microbial pathogens to infect and invade the host, such as adherence, colonization, invasion, production of biofilms and production of virulence factors such as proteases and toxins. Lf can also cause mitochondrial and caspase-dependent regulated cell death and apoptosis-like in pathogenic yeasts. All of these mechanisms are important targets for treatment with Lf. Holo-Lf (the iron-saturated molecule) can contain up to two ferric ions and can also be microbicidal against some pathogens. On the other hand, lactoferricins (Lfcins) are peptides derived from the N-terminus of Lf that are produced by proteolysis with pepsin under acidic conditions, and they cause similar effects on pathogens to those caused by the parental Lf. Synthetic analog peptides comprising the N-terminus Lf region similarly exhibit potent antimicrobial properties. Importantly, there are no reported pathogens that are resistant to Lf and Lfcins; in addition, Lf and Lfcins have shown a synergistic effect with antimicrobial and antiviral drugs. Due to the Lf properties being microbiostatic, microbicidal, anti-inflammatory and an immune modulator, it represents an excellent natural alternative either alone or as adjuvant in the combat to antibiotic multidrug-resistant bacteria and other pathogens. This review aimed to evaluate the data that appeared in the literature about the effects of Lf and its derived peptides on pathogenic bacteria, protozoa, fungi and viruses and how Lf and Lfcins inhibit the mechanisms developed by these pathogens to cause disease.

Entities:  

Keywords:  antimicrobial; lactoferricins; lactoferrin; pathogenicity mechanisms; virulence factors

Mesh:

Substances:

Year:  2020        PMID: 33302377      PMCID: PMC7762604          DOI: 10.3390/molecules25245763

Source DB:  PubMed          Journal:  Molecules        ISSN: 1420-3049            Impact factor:   4.411


  236 in total

Review 1.  Occurrence, structure, biochemical properties and technological characteristics of lactoferrin.

Authors:  J M Steijns; A C van Hooijdonk
Journal:  Br J Nutr       Date:  2000-11       Impact factor: 3.718

Review 2.  Viral entry.

Authors:  S B Sieczkarski; G R Whittaker
Journal:  Curr Top Microbiol Immunol       Date:  2005       Impact factor: 4.291

3.  Toxoplasma gondii: inhibition of the intracellular growth by human lactoferrin.

Authors:  Katarzyna Dzitko; Bozena Dziadek; Jarosław Dziadek; Henryka Długońska
Journal:  Pol J Microbiol       Date:  2007

Review 4.  Potential lactoferrin activity against pathogenic viruses.

Authors:  Elrashdy M Redwan; Vladimir N Uversky; Esmail M El-Fakharany; Hussein Al-Mehdar
Journal:  C R Biol       Date:  2014-09-22       Impact factor: 1.583

5.  Lactoferrin inhibits Porphyromonas gingivalis proteinases and has sustained biofilm inhibitory activity.

Authors:  Stuart G Dashper; Yu Pan; Paul D Veith; Yu-Yen Chen; Elena C Y Toh; Sze Wei Liu; Keith J Cross; Eric C Reynolds
Journal:  Antimicrob Agents Chemother       Date:  2012-01-03       Impact factor: 5.191

Review 6.  Human lactoferrin: a novel therapeutic with broad spectrum potential.

Authors:  E D Weinberg
Journal:  J Pharm Pharmacol       Date:  2001-10       Impact factor: 3.765

7.  Shiga toxin subtypes display dramatic differences in potency.

Authors:  Cynthia A Fuller; Christine A Pellino; Michael J Flagler; Jane E Strasser; Alison A Weiss
Journal:  Infect Immun       Date:  2011-01-03       Impact factor: 3.441

8.  Different anti-Candida activities of two human lactoferrin-derived peptides, Lfpep and kaliocin-1.

Authors:  Mónica Viejo-Díaz; María T Andrés; José F Fierro
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

Review 9.  Studying Lactoferrin N-Glycosylation.

Authors:  Sercan Karav; J Bruce German; Camille Rouquié; Annabelle Le Parc; Daniela Barile
Journal:  Int J Mol Sci       Date:  2017-04-20       Impact factor: 5.923

10.  Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia: The Hidden Enemy?

Authors:  Antoni Torres; Ignacio Martin-Loeches
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

View more
  8 in total

1.  Lactotransferrin promotes intervertebral disc degeneration by regulating Fas and inhibiting human nucleus pulposus cell apoptosis.

Authors:  Xiao-Bo Zhang; Si-Qi Xu; Yi-Geng Hui; Hai-Yu Zhou; Yi-Cun Hu; Rui-Hao Zhang; Xi-Dan Gao; Chang-Ming Zheng
Journal:  Aging (Albany NY)       Date:  2022-05-25       Impact factor: 5.955

Review 2.  Diverse Mechanisms of Antimicrobial Activities of Lactoferrins, Lactoferricins, and Other Lactoferrin-Derived Peptides.

Authors:  Špela Gruden; Nataša Poklar Ulrih
Journal:  Int J Mol Sci       Date:  2021-10-19       Impact factor: 5.923

Review 3.  Lactoferrin: A Nutraceutical with Activity against Colorectal Cancer.

Authors:  Gerardo Ramírez-Rico; Maria Elisa Drago-Serrano; Nidia León-Sicairos; Mireya de la Garza
Journal:  Front Pharmacol       Date:  2022-02-21       Impact factor: 5.810

4.  Investigating mammary glands of lactating goats for the presence of tertiary lymphoid organs.

Authors:  Yusaku Tsugami; Sayaka Nakayama; Naoki Suzuki; Takahiro Nii; Naoki Isobe
Journal:  Front Immunol       Date:  2022-08-10       Impact factor: 8.786

Review 5.  Antimicrobial peptides: Defending the mucosal epithelial barrier.

Authors:  Karen F Johnstone; Mark C Herzberg
Journal:  Front Oral Health       Date:  2022-08-01

6.  Blockade of TMPRSS2-mediated priming of SARS-CoV-2 by lactoferricin.

Authors:  Anna Ohradanova-Repic; Rostislav Skrabana; Laura Gebetsberger; Gabor Tajti; Peter Baráth; Gabriela Ondrovičová; Romana Praženicová; Nikola Jantova; Patricia Hrasnova; Hannes Stockinger; Vladimir Leksa
Journal:  Front Immunol       Date:  2022-08-23       Impact factor: 8.786

Review 7.  Activity of Apo-Lactoferrin on Pathogenic Protozoa.

Authors:  Magda Reyes-López; Gerardo Ramírez-Rico; Jesús Serrano-Luna; Mireya de la Garza
Journal:  Pharmaceutics       Date:  2022-08-15       Impact factor: 6.525

Review 8.  Physicochemical Features and Peculiarities of Interaction of AMP with the Membrane.

Authors:  Malak Pirtskhalava; Boris Vishnepolsky; Maya Grigolava; Grigol Managadze
Journal:  Pharmaceuticals (Basel)       Date:  2021-05-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.